Dr. Tony Hunter is Director of the Cancer Center. He devotes 50% effort to his role as Director. His Duties and responsibilities include coordination, planning and development of the research activities of the Cancer Center, appointment of members, administration of the CCSG budget, assuring the scientific and fiscal stability of Center research programs, oversight of and development of shared resources, encouragement of collaborations and enhancement of scientific excellence. Dr. Hunter's qualifications and experience include more than 35 years of research on viral oncogenes, mechanisms of transformation, cell growth and cell cycle control. He has received a number of prestigious awards for his research, including the General Motors Cancer Research Foundation Mott Prize, the American Cancer Society Medal of Honor, and the AACR Landon Prixe for Basic Cancer Research. He has been an American Cancer Society Research Professor since 1993. He is the recipient of three individual research grants from the NCI and served on the Board of Scientific Councilors of the NCI from 1996-1999. He has been co-PI of the CCSG for the past five years. Dr. Hunter's qualifications and role are described in more detail in Section 6.6, Center Director.

Public Health Relevance

The research mission of the Cancer Center is to understand the fundamental aspects of biology related to cancer. Leadership from experienced and respected investigators is critical to carry out the mission of the Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014195-44
Application #
9185278
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
44
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Salk Institute for Biological Studies
Department
Type
DUNS #
078731668
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Evan, Gerard I; Hah, Nasun; Littlewood, Trevor D et al. (2017) Re-engineering the Pancreas Tumor Microenvironment: A ""Regenerative Program"" Hacked. Clin Cancer Res 23:1647-1655
Liu, Hao; Naxerova, Kamila; Pinter, Matthias et al. (2017) Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 23:5959-5969
Gasser, Emanuel; Moutos, Christopher P; Downes, Michael et al. (2017) FGF1 - a new weapon to control type 2 diabetes mellitus. Nat Rev Endocrinol 13:599-609
Chen, Peiwen; Zuo, Hao; Xiong, Hu et al. (2017) Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A 114:580-585
Manoogian, Emily N C; Panda, Satchidananda (2017) Circadian rhythms, time-restricted feeding, and healthy aging. Ageing Res Rev 39:59-67
Fan, Weiwei; Waizenegger, Wanda; Lin, Chun Shi et al. (2017) PPAR? Promotes Running Endurance by Preserving Glucose. Cell Metab 25:1186-1193.e4
Tufail, Yusuf; Cook, Daniela; Fourgeaud, Lawrence et al. (2017) Phosphatidylserine Exposure Controls Viral Innate Immune Responses by Microglia. Neuron 93:574-586.e8
Li, Dongming; Palanca, Ana Marie S; Won, So Youn et al. (2017) The MBD7 complex promotes expression of methylated transgenes without significantly altering their methylation status. Elife 6:
Wu, Min-Zu; Cheng, Wei-Chung; Chen, Su-Feng et al. (2017) miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS. Nat Cell Biol 19:1286-1296
Doktorova, Marcela; Zwarts, Irene; Zutphen, Tim van et al. (2017) Intestinal PPAR? protects against diet-induced obesity, insulin resistance and dyslipidemia. Sci Rep 7:846

Showing the most recent 10 out of 429 publications